Table 1.
Characteristics | N (%) or median (range) |
---|---|
Total | 53 (100%) |
Age (mean ± SD, years) | 56.9 years (range, 37-75 years) |
Lower age (≤60 years) | 31 (58.5%) |
Higher age (>60 years) | 22 (41.5%) |
Gender | |
Male | 45 (84.9%) |
Female | 8 (15.1%) |
Bodyweight, kg | |
<60 | 20 (37.7%) |
≥60 | 33 (62.3%) |
ECOG PS | |
0 | 34 (64.2%) |
1 | 19 (35.8%) |
AFP (ng/ml) | |
Low (<400) | 35 (66.0%) |
High (≥400) | 18 (34.0%) |
Liver cirrhosis | |
No | 45 (84.9%) |
Yes | 8 (15.1%) |
Child-pugh score | |
5 | 19 (35.8%) |
6 | 15 (28.3%) |
7 | 19 (35.8%) |
Etiology | |
HBV | 45 (84.9%) |
HCV | 5 (9.4%) |
Alcohol | 3 (5.7%) |
Vascular invasion | |
No | 28 (52.8%) |
Yes | 25 (47.2%) |
Extrahepatic metastasis | |
Lung | 10 (18.9%) |
Lymph node | 21 (39.6%) |
Bone | 6 (11.3%) |
Other | 5 (9.4%) |
BCLC stage | |
B | 23 (43.4%) |
C | 30 (56.6%) |
Prior therapies | |
Surgery | 9 (17.0%) |
Ablation | 29 (54.7%) |
TACE | 33 (62.3%) |
TKIs | 24 (45.3%) |
PD-1 inhibitors | |
Camrelizumab | 25 (47.2%) |
Sintilimab | 28 (52.8%) |